Denis N Kisakov, Igor M Belyakov, Lubov A Kisakova, Vladimir A Yakovlev, Elena V Tigeeva, Larisa I Karpenko. The use of electroporation to deliver DNA-based vaccines.Expert review of vaccines. 2024, 23 (1): 102-123
Myron J Levin, Victoria Divino, Maarten J Postma, Stephen I Pelton, Zifan Zhou, Mitch DeKoven, Joaquin Mould-Quevedo. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons.Expert review of vaccines. 2024, 23 (1): 124-136
Timothy J Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston, Gretchen Tamms, Robert Lupinacci, Kristen Feemster, Ulrike K Buchwald, Natalie Banniettis. PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children.Expert review of vaccines. 2024, 23 (1): 137-147
Juntao Yin, Liang Zhang, Chaoyang Wang, Changjiang Qin, Mingsan Miao. Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials.Expert review of vaccines. 2024, 23 (1): 148-159
Karan Thakkar, Julia Spinardi, Moe H Kyaw, Jingyan Yang, Carlos Fernando Mendoza, Egemen Ozbilgili, Bulent Taysi, Josie Dodd, Ben Yarnoff, Helen M Oh. Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore.Expert review of vaccines. 2024, 23 (1): 16-26
Chiara de Waure, Barbara C Gärtner, Pier Luigi Lopalco, Joan Puig-Barbera, Jonathan S Nguyen-Van-Tam. Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable.Expert review of vaccines. 2024, 23 (1): 27-38
Thi Hoai Thu Do, Adam K Wheatley, Stephen J Kent, Marios Koutsakos. Influenza B virus neuraminidase: a potential target for next-generation vaccines?Expert review of vaccines. 2024, 23 (1): 39-48
Elizabeth Adrianne Hammershaimb, Andrea A Berry. Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond.Expert review of vaccines. 2024, 23 (1): 49-52
Yiming Li, Sori K Lundin, Jianfu Li, Wei Tao, Yifang Dang, Yong Chen, Cui Tao. Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data.Expert review of vaccines. 2024, 23 (1): 53-59
Josiah Ryman, Jeffrey R Sachs, Ka Lai Yee, Natalie Banniettis, Jessica Weaver, Thomas Weiss. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.Expert review of vaccines. 2024, 23 (1): 60-68
Francesco Lapi, Ettore Marconi, Elettra Fallani, Marco Salvatore, Maura Cambiaggi, Alessandro Rossi, Claudio Cricelli. Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons in Italy.Expert review of vaccines. 2024, 23 (1): 8-15
Stephen I Pelton, Joaquin F Mould-Quevedo, Van Hung Nguyen. Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.Expert review of vaccines. 2024, 23 (1): 82-87
Laura Colombo, Sanjay Hadigal, Jos Nauta, Alona Kondratenko, Jutta Rogoll, Serge Van de Witte. Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity.Expert review of vaccines. 2024, 23 (1): 88-101